Home›Legal›Semaglutide in Pennsylvania
Semaglutide in Pennsylvania: Legal Status & Provider Guide (2026)
Quick Answer
Semaglutide is a prescription substance in the United States. Semaglutide is an FDA-approved drug. Compounded versions were temporarily permitted during a drug shortage that ended in early 2025. Current federal law generally prohibits 503A/503B compounding of semaglutide except for narrow clinical exceptions. Patients should verify their provider's legal basis for offering compounded semaglutide. In Pennsylvania, compounding is governed by the Pennsylvania State Board of Pharmacy (PSBP). Pennsylvania certified registered nurse practitioners (CRNPs) may prescribe compounded medications including peptides within a collaborative agreement. Physician assistants also require supervision agreements. Pennsylvania has moderately permissive telehealth rules, allowing prescribing after an appropriate telehealth evaluation. Pennsylvania prescribers must hold an active Pennsylvania license to prescribe to Pennsylvania residents.
Federal Legal Status
FDA Approval Status
FDA-approved as Ozempic (type 2 diabetes, 2017), Wegovy (chronic weight management, 2021), and Rybelsus (oral, type 2 diabetes, 2019). Compounded semaglutide was permitted during shortage but FDA declared shortage resolved in March 2025.
Compounding Pharmacy Rules (Federal)
Compounding of semaglutide was broadly permitted under shortage exemptions through early 2025. Following FDA's March 2025 shortage resolution declaration, 503B outsourcing facilities had a wind-down period through April 2025, and 503A pharmacies through May 2025. As of mid-2025, compounded semaglutide is generally prohibited except for specific patient needs (e.g., documented allergy to an inactive ingredient in the commercially available product) under a valid prescription.
Also Known As
Ozempic · Wegovy · Rybelsus
Primary Research Areas
- Weight management
- Type 2 diabetes
- Cardiovascular risk reduction
- Metabolic health
Pennsylvania Pharmacy Board & Compounding Rules
Compounding Overview
Pennsylvania's State Board of Pharmacy regulates compounding pharmacies with detailed sterile and non-sterile compounding standards. Pennsylvania has historically been home to several large-scale compounding operations. The state enforces USP 797 standards for sterile products and requires annual inspections for high-risk compounding. Pennsylvania is part of the northeastern corridor with significant demand from New York, New Jersey, and Delaware markets.
Notable Rules
- Pennsylvania requires pharmacies engaged in sterile compounding to have a separate license category.
- Annual inspections are required for pharmacies performing high-risk sterile compounding.
- Pennsylvania shares regulatory burden with the FDA for pharmacies also registered as 503B outsourcing facilities.
- Non-resident pharmacies shipping compounds into Pennsylvania must be registered with the PSBP.
- Pennsylvania and New York maintain some reciprocal licensing arrangements for pharmacy professionals.
Prescribing Requirements in Pennsylvania
Pennsylvania certified registered nurse practitioners (CRNPs) may prescribe compounded medications including peptides within a collaborative agreement. Physician assistants also require supervision agreements. Pennsylvania has moderately permissive telehealth rules, allowing prescribing after an appropriate telehealth evaluation. Pennsylvania prescribers must hold an active Pennsylvania license to prescribe to Pennsylvania residents.
About Semaglutide
Semaglutide is a GLP-1 receptor agonist originally developed by Novo Nordisk. It is FDA-approved for type 2 diabetes and chronic weight management and is among the most studied compounds in contemporary metabolic medicine.
For more research information, mechanism of action, and provider availability, see the Semaglutide research profile on PeptideBase.
Frequently Asked Questions
- Is compounded semaglutide legal in 2026?
- FDA declared the semaglutide shortage resolved in March 2025. After wind-down periods, compounding of semaglutide is generally prohibited for 503A and 503B facilities. Narrow exceptions exist for documented allergies to commercially available formulations. Patients should ask providers for the specific legal basis for any compounded product.
- What is the difference between Ozempic, Wegovy, and compounded semaglutide?
- Ozempic (0.5–2 mg weekly injection) is approved for type 2 diabetes. Wegovy (2.4 mg weekly injection) is approved for chronic weight management. Compounded semaglutide was chemically equivalent but manufactured by compounding pharmacies — a practice now restricted following the shortage resolution.
Semaglutide Providers in Pennsylvania
No providers currently listed in Pennsylvania for Semaglutide. Browse the full directory to find providers offering Semaglutide.
Browse all Semaglutide providers →Semaglutide Legal Status in Other States
Pharmacy board rules and compounding regulations vary by state. Compare Semaglutide legal status across other major markets:
Content review: This educational overview is prepared by the PeptideBase editorial team and reviewed for factual accuracy. Reviewer byline coming soon (gated on 4.4). Last updated: .